🔗 Share this article

While the US continues making unprecedented changes to its vaccination guidelines, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by casting doubt on coronavirus vaccines in the global health crisis and has zeroed in on possible deaths after Covid immunization in her brief position at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Program

Public health authorities were set to reveal radical changes to the pediatric vaccine schedule in December, bringing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of step with many the international standard with insufficient data for benefit. This reveal has been delayed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for halting specific pediatric shot schedules in the US to become more in line with the Danish model, a society with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent track record in pharmaceutical research, regulation or administrative roles, which has been customary for previous leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have the necessary background” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in leading a major agency. She has no expertise in drug approvals.”

Former directors of CBER would “be deeply familiar with legal statutes and the science of drug development”, said a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that prior appointees who ran the center have had.”

The drug center has an vast portfolio at the FDA, Woodcock emphasized.

“Everybody just focuses on the new drug program, but the off-patent medication office clears numerous generic drugs. There is also a biosimilars program, over-the-counter program and other areas, and every single one must be looked after,” Dr. Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial leadership aspect to the position, which manages in excess of 5,000 staff members. “It is a huge management job, if you execute it properly,” she said.

Response and Disputed Programs

Regarding concerns about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among agency officials on vaccines, a representative responded that the “inquiries stem from incorrect assumptions”.

“Her experience is consistent with the responsibilities of her job,” the representative stated, pointing to the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's new fast-track approval initiative, a contentious one-day therapy clearance system that reportedly concerned her predecessors. “How are these drugs being selected for this voucher program? Who makes the decisions?” Dr. Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards less stringent rules of all drugs, except for immunizations.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if concerning, track record, critics observe. She published a analysis using non-validated volunteer-provided data to determine the rate of heart inflammation following COVID-19 immunization. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Among her “desired changes” for the current government featured altering guidelines for new vaccines and halting “optional” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has reportedly floated the idea of barring adolescent males from receiving Covid vaccinations.

“She’s an all-around ideologue who starts off with her beliefs and works backwards to retrofit the evidence in a very misleading, dishonest way,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|